Literature DB >> 28302417

MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.

Hasan Rajabi1, Donald Kufe2.   

Abstract

The MUC1 gene evolved in mammalian species to provide protection of epithelia. The transmembrane MUC1 C-terminal subunit (MUC1-C) signals stress to the interior of the epithelial cell and, when overexpressed as in most carcinomas, functions as an oncoprotein. MUC1-C induces the epithelial-mesenchymal transition (EMT) by activating the inflammatory NF-κB p65 pathway and, in turn, the EMT-transcriptional repressor ZEB1. Emerging evidence has indicated that MUC1-C drives a program integrating the induction of EMT with activation of stem cell traits, epigenetic reprogramming and immune evasion. This mini-review focuses on the potential importance of this MUC1-C program in cancer progression.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BMI1; DNMTs; EMT; MUC1-C; PD-L1; epigenetics; immune evasion; tumor suppressor genes

Mesh：

Substances：

Year:  2017        PMID： 28302417      PMCID： PMC5548633          DOI： 10.1016/j.bbcan.2017.03.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN： 0304-419X            Impact factor:   10.680


  55 in total

1.  MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90.

Authors:  J Ren; A Bharti; D Raina; W Chen; R Ahmad; D Kufe
Journal:  Oncogene       Date:  2006-01-05       Impact factor: 9.867

2.  MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells.

Authors:  Hasan Rajabi; Rehan Ahmad; Caining Jin; Michio Kosugi; Maroof Alam; Maya Datt Joshi; Donald Kufe
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

3.  Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency.

Authors:  Jasmine M De Cock; Tsukasa Shibue; Anushka Dongre; Zuzana Keckesova; Ferenc Reinhardt; Robert A Weinberg
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

4.  Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

Authors:  Masanori Hasegawa; Raj Kumar Sinha; Manoj Kumar; Maroof Alam; Li Yin; Deepak Raina; Akriti Kharbanda; Govind Panchamoorthy; Dikshi Gupta; Harpal Singh; Surender Kharbanda; Donald Kufe
Journal:  Clin Cancer Res       Date:  2015-02-23       Impact factor: 12.531

Review 5.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

6.  The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.

Authors:  Selvi Ramasamy; Sekhar Duraisamy; Sergei Barbashov; Takeshi Kawano; Surender Kharbanda; Donald Kufe
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

7.  Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62.

Authors:  Yumei Leng; Cheng Cao; Jian Ren; Lei Huang; Dongshu Chen; Masaki Ito; Donald Kufe
Journal:  J Biol Chem       Date:  2007-05-11       Impact factor: 5.157

8.  MUC1-C activates BMI1 in human cancer cells.

Authors:  M Hiraki; T Maeda; A Bouillez; M Alam; A Tagde; K Hinohara; Y Suzuki; T Markert; M Miyo; K Komura; R Ahmad; H Rajabi; D Kufe
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

9.  Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.

Authors:  Deepak Raina; Praveen Agarwal; James Lee; Ajit Bharti; C James McKnight; Pankaj Sharma; Surender Kharbanda; Donald Kufe
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

10.  Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway.

Authors:  Chih-Hsing Chou; Miao-Juei Huang; Chi-Hau Chen; Ming-Kwang Shyu; John Huang; Ji-Shiang Hung; Chiun-Sheng Huang; Min-Chuan Huang
Journal:  Oncotarget       Date:  2015-03-20
View more
  40 in total

Review 1.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

2.  A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.

Authors:  Margaret E Gatti-Mays; Julius Strauss; Jeffrey Schlom; James L Gulley; Renee N Donahue; Claudia Palena; Jaydira Del Rivero; Jason M Redman; Ravi A Madan; Jennifer L Marté; Lisa M Cordes; Elizabeth Lamping; Alanvin Orpia; Andrea Burmeister; Eva Wagner; Cesar Pico Navarro; Christopher R Heery
Journal:  Clin Cancer Res       Date:  2019-05-20       Impact factor: 12.531

3.  Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.

Authors:  Govind Panchamoorthy; Caining Jin; Deepak Raina; Ajit Bharti; Masaaki Yamamoto; Dennis Adeebge; Qing Zhao; Roderick Bronson; Shirley Jiang; Linjing Li; Yozo Suzuki; Ashujit Tagde; P Peter Ghoroghchian; Kwok-Kin Wong; Surender Kharbanda; Donald Kufe
Journal:  JCI Insight       Date:  2018-06-21

4.  MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Hidekazu Takahashi; Yota Yasumizu; Wei Li; Caining Jin; Mark D Long; Qiang Hu; Song Liu; Atsushi Fushimi; Nami Yamashita; Ling Kui; Deli Hong; Masaaki Yamamoto; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Mehmet K Samur; Donald Kufe
Journal:  Cancer Res       Date:  2019-09-13       Impact factor: 12.701

5.  MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

Authors:  Masaaki Yamamoto; Caining Jin; Tsuyoshi Hata; Yota Yasumizu; Yan Zhang; Deli Hong; Takahiro Maeda; Masaaki Miyo; Masayuki Hiraki; Yozo Suzuki; Kunihiko Hinohara; Hasan Rajabi; Donald Kufe
Journal:  Cancer Res       Date:  2019-03-01       Impact factor: 12.701

6.  MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.

Authors:  Audrey Bouillez; Dennis Adeegbe; Caining Jin; Xiufeng Hu; Ashujit Tagde; Maroof Alam; Hasan Rajabi; Kwok-Kin Wong; Donald Kufe
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

7.  MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Authors:  Takahiro Maeda; Masayuki Hiraki; Caining Jin; Hasan Rajabi; Ashujit Tagde; Maroof Alam; Audrey Bouillez; Xiufeng Hu; Yozo Suzuki; Masaaki Miyo; Tsuyoshi Hata; Kunihiko Hinohara; Donald Kufe
Journal:  Cancer Res       Date:  2017-12-20       Impact factor: 12.701

8.  Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Masaaki Yamamoto; Caining Jin; Rehan Ahmad; Yan Zhang; Ling Kui; Wei Li; Yota Yasumizu; Deli Hong; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Hidekazu Takahashi; Mehmet Samur; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2019-07-15       Impact factor: 6.261

Review 9.  MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.

Authors:  Hasan Rajabi; Masayuki Hiraki; Donald Kufe
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

Review 10.  MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.

Authors:  Wenqing Chen; Zhu Zhang; Shiqing Zhang; Peili Zhu; Joshua Ka-Shun Ko; Ken Kin-Lam Yung
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.